NRG Oncology
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2014-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.nrgoncology.org
Flatiron Health and NRG Oncology Partner to Streamline Clinical Trial Data Management with EHR-to-EDC Technology
• Flatiron Health and NRG Oncology have partnered to implement Flatiron Clinical Pipe, an EHR-to-EDC connector technology, in a multi-center oncology trial to enhance data entry efficiency.
• The technology enables rapid transfer of thousands of data points directly from electronic health records, eliminating the need for source data verification and potentially reducing administrative burden on research staff.
• A correlative study will be conducted alongside the implementation to evaluate the efficiency of Flatiron Clinical Pipe compared to traditional data entry methods in clinical trials.
University of Colorado Cancer Center Partners with Flatiron Health to Streamline Clinical Trial Data Management
• Flatiron Health and University of Colorado Cancer Center launch collaboration to implement Clinical Pipe™, an advanced EHR-to-EDC connector that streamlines clinical trial data capture.
• The technology demonstrates remarkable efficiency, enabling transfer of over 11,000 data points with average submission times of just 37 seconds, significantly reducing administrative burden.
• This partnership aims to expand clinical trial access and accelerate cancer research by automating data entry processes across UCHealth's network of care facilities.
UCSF Performs World's First OnQ Prostate-Assisted Robotic HIFU Procedure
• Cortechs.ai and EDAP TMS SA achieved a milestone with the first-ever OnQ Prostate-assisted Focal One Robotic HIFU procedure performed at UCSF Prostate Center.
• UCLA researchers found that early radiation therapy side effects in prostate cancer patients may indicate higher risks of serious long-term urinary and bowel complications.
• Vanderbilt researchers discovered that the inherited mutated WNT9B gene, crucial in embryonic prostate development, increases adult prostate cancer risk.
Exact Sciences' Oncodetect Shows Promise in Detecting Residual Colorectal Cancer
• Exact Sciences' Oncodetect MRD test demonstrates strong performance in detecting molecular residual disease in colorectal cancer patients, according to new clinical validation data.
• The Alpha-CORRECT study showed Oncodetect achieved 78% sensitivity post-surgery and 91% during surveillance, with 80% and 94% specificity, respectively.
• Beta-CORRECT study confirms a significant association between MRD positivity and recurrence in stage III colon cancer, extending prognostic value to other stages.
• Exact Sciences plans to launch Oncodetect in Q2 2025 with Medicare coverage, supported by strategic partnerships for multi-cancer evidence generation.
European Commission Approves GSK's Jemperli Plus Chemotherapy for Advanced Endometrial Cancer
• The European Commission has approved Jemperli (dostarlimab) in combination with chemotherapy for first-line treatment of advanced or recurrent endometrial cancer.
• The approval expands the indication to include patients with mismatch repair proficient/microsatellite stable (MMRp/MSS) tumors, representing approximately 75% of cases.
• The RUBY trial demonstrated a 31% reduction in the risk of death with Jemperli plus chemotherapy compared to chemotherapy alone, with a median OS of 44.6 months.
• Jemperli, a PD-1 blocking antibody, is now an approved immuno-oncology-based treatment option for all patients with advanced endometrial cancer in the EU.
NRG258 Trial: Chemoradiation Fails to Improve Overall Survival in Advanced Endometrial Cancer
• Long-term follow-up of the NRG258 phase III trial reveals no significant difference in overall survival between adjuvant chemoradiation and chemotherapy alone for locally advanced endometrial carcinoma.
• The study, involving 736 patients, showed that chemoradiation did not improve recurrence-free survival compared to chemotherapy alone, despite reducing local recurrence rates.
• Subgroup analyses found no significant benefit of chemoradiation based on FIGO stage, age, race, histology, or other clinical factors, indicating limited applicability.
• The findings suggest that chemotherapy alone remains a standard treatment option for stage III/IVA endometrial cancer, challenging the role of adjuvant chemoradiation in this setting.
Neoadjuvant or Concurrent Atezolizumab with Chemoradiation for Locally Advanced Cervical Cancer
A clinical trial investigated the efficacy and safety of neoadjuvant or concurrent atezolizumab with chemoradiation in patients with locally advanced cervical cancer. The study involved 36 eligible patients, showing promising 2-year disease-free survival rates and exploring the evolution of T-cell receptor repertoire in response to therapy.
SBRT Followed by Chemoradiotherapy Shows Promise in Locally Advanced NSCLC
• A phase II trial evaluated stereotactic body radiotherapy (SBRT) to the primary lung tumor followed by chemoradiotherapy and consolidation immunotherapy in locally advanced NSCLC.
• The study did not meet its primary endpoint of 1-year progression-free survival, but showed favorable activity and safety profiles compared to other trials.
• Patients receiving consolidation durvalumab showed improved 1-year progression-free survival compared to the historical control rate.
• The findings support further investigation in the ongoing randomized phase 3 study NRG Oncology LU008.
Tamoxifen Reduces Long-Term Recurrence Risk in Good-Risk DCIS Without Radiation
• Adjuvant tamoxifen significantly reduces the 15-year risk of ipsilateral breast cancer recurrence in patients with good-risk DCIS who forgo radiation therapy.
• Tamoxifen notably decreases the risk of invasive ipsilateral breast cancer recurrence but does not significantly impact ipsilateral DCIS or contralateral breast cancer.
• The findings support tamoxifen as a reasonable option for good-risk DCIS patients post-surgery, aiding in informed decisions between endocrine and radiation therapies.
• The study underscores the importance of evaluating endocrine therapy's impact in patients with good-risk DCIS who do not receive radiation therapy.
Lynparza Demonstrates Prolonged Survival Benefit in Early Breast Cancer with BRCA Mutation
• Lynparza (olaparib) shows sustained improvement in overall survival for patients with germline BRCA-mutated, HER2-negative, high-risk early breast cancer.
• The OlympiA Phase III trial reveals a 28% reduction in the risk of death with Lynparza compared to placebo after a median follow-up of 6.1 years.
• Treatment with Lynparza also significantly improves invasive disease-free survival and distant disease-free survival, reducing recurrence risks.
• The safety profile of Lynparza remains consistent with previous trials, with no new safety concerns identified in the long-term follow-up.
Olaparib Shows Sustained Benefit in Early-Stage BRCA-Mutated Breast Cancer
• Olaparib improves long-term survival in women with high-risk, early-stage breast cancer and BRCA1/2 mutations, reducing cancer recurrence risk by 35%.
• After six years, 87.5% of olaparib-treated patients were alive, compared to 83.2% in the placebo group, demonstrating a significant survival advantage.
• The OlympiA trial reinforces the importance of BRCA testing to identify patients who can benefit from personalized olaparib treatment early.
• Olaparib is now recommended by NICE in England and Wales for early-stage, high-risk breast cancer with BRCA1/2 mutations, improving survival chances.
NRG Oncology/Alliance LU005 Trial: Atezolizumab Fails to Improve Survival in Limited-Stage SCLC
• The NRG Oncology/Alliance LU005 trial found that adding atezolizumab to standard chemoradiotherapy (CRT) did not significantly improve overall survival in patients with limited-stage small-cell lung cancer (LS-SCLC).
• Median overall survival was 39 months in the CRT-only arm and 33 months in the atezolizumab arm, indicating no benefit from the addition of immunotherapy in this setting.
• The study suggests twice-daily radiation therapy may be associated with improved survival compared to once-daily radiation therapy in LS-SCLC patients.
• Experts emphasize the importance of timing and potential interference of extensive radiation with the effectiveness of immunotherapy, warranting further investigation.
Durvalumab Fails to Improve Outcomes Over Cetuximab in Head and Neck Cancer
• A phase 2/3 trial (NRG-HN004) found that durvalumab did not improve outcomes compared to cetuximab in patients with locoregionally advanced head and neck squamous cell carcinoma (HNSCC) who have contraindications to cisplatin.
• Progression-free survival at 2 years was 50.6% in the durvalumab group and 63.7% in the cetuximab group, indicating cetuximab's superior efficacy in this patient population.
• The trial was stopped early due to futility, with an interim analysis suggesting durvalumab with radiotherapy was unlikely to improve outcomes over cetuximab with radiotherapy.
• The findings suggest cetuximab remains a viable alternative for patients with HNSCC who cannot receive cisplatin, informing future trial designs for this understudied population.
Diversity in Head and Neck Cancer Clinical Trials Declines, Study Finds
• A recent study reveals that racial and ethnic diversity in head and neck cancer clinical trials in the U.S. has worsened over the past decade.
• The research highlights a critical disparity, indicating that race and gender can significantly impact a patient's access to potentially life-saving cancer treatments.
• Boston Medical Center initiatives show promise, achieving 58% participation from underrepresented groups in head and neck cancer trials, contrasting with national averages of 7-12%.
• Researchers emphasize the urgent need for novel strategies to enhance inclusivity in clinical trials, ensuring equitable access to effective treatments for all patients.
Circulating Tumor Cell Count Predicts Survival in Metastatic Hormone-Sensitive Prostate Cancer
• A new study reveals that circulating tumor cell (CTC) count is significantly associated with overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC) patients.
• Patients with higher CTC counts (≥5 cells/7.5 mL) at baseline had significantly shorter OS compared to those with lower counts (<5 cells/7.5 mL).
• The study suggests CTC count could serve as a prognostic biomarker to guide treatment decisions and monitor disease progression in mHSPC.
• Findings highlight the potential of liquid biopsies in personalizing treatment strategies for prostate cancer patients.
Blood Test Predicts Survival in Men Newly Diagnosed With Metastatic Prostate Cancer
• A new blood test can predict treatment response and survival in men newly diagnosed with metastatic hormone-sensitive prostate cancer (mHSPC).
• The test measures circulating tumor cells (CTCs); higher counts indicate poorer outcomes, including shorter survival and faster disease progression.
• The CellSearch test, already FDA-cleared, can identify patients who may benefit from more aggressive therapies or clinical trial participation.
• Measuring CTC levels at the start of therapy can predict long-term survival, aiding in personalized treatment strategies for advanced prostate cancer.
Cognitive Function Can Recover in Cancer Patients After Brain Radiation, Study Suggests
• A new study reveals that nearly 40% of cancer patients who experience cognitive decline after brain radiation therapy can regain full neurocognitive function within six months.
• The research indicates that patients receiving highly targeted radiation treatments are more likely to recover cognitive function compared to those undergoing standard whole-brain radiation.
• Cognitive recovery was defined as having no evidence of impairment based on a series of sophisticated cognitive tests, highlighting the potential for long-term improvement.
• The findings may help physicians counsel their patients about treatment options and recovery from potential cognitive side effects, shifting the view of cognitive dysfunction as a non-permanent endpoint.
NRG Oncology Trial: Radiotherapy and Cisplatin Remain Standard of Care for p16+ Oropharyngeal Cancer
• The NRG-HN005 phase II/III trial found that de-intensified treatment arms were inferior to standard radiotherapy and cisplatin for p16+ oropharyngeal cancer.
• The control arm, using standard chemoradiation, demonstrated a 98.1% 2-year progression-free survival rate, setting a high benchmark for future studies.
• The study enrolled 384 patients with p16+ oropharyngeal squamous cell carcinoma, comparing standard treatment to lower-dose IMRT with chemotherapy or immunotherapy.
• Findings affirm the efficacy of traditional chemoradiation for this patient group and highlight the challenges in improving upon current standards.
Standard Chemoradiation Shows Superior Outcomes in HPV-Associated Oropharyngeal Cancer
• A phase II/III trial (NRG Oncology HN005) revealed a 98% two-year progression-free survival rate with standard chemoradiation for HPV-associated oropharyngeal cancer, a record high.
• De-intensified treatments, involving lower radiation doses and immunotherapy (nivolumab) instead of chemotherapy, did not match the efficacy of standard chemoradiation.
• Experts emphasize that de-intensification strategies should remain experimental, requiring further research to minimize side effects while maintaining high cure rates.
• The findings set a new benchmark for progression-free survival expectations, challenging the validity of phase II trials using lower standards for this patient population.
Atezolizumab Plus Chemoradiation Fails to Improve Survival in Limited-Stage SCLC
• A phase 3 trial (NRG-LU005) showed that adding atezolizumab to chemoradiation did not improve overall survival (OS) in patients with limited-stage small cell lung cancer (LS-SCLC).
• Median OS was 39.5 months with chemoradiation alone versus 33.1 months with atezolizumab plus chemoradiation (HR, 1.11; P = .7640), indicating no significant benefit.
• The study suggests the timing of immunotherapy with chemoradiation is crucial, as previous research showed benefit when immunotherapy was given sequentially.
• Twice-daily radiation showed improved survival compared to once-daily radiation, regardless of atezolizumab administration (HR, 1.45; P = .0075).
© Copyright 2025. All Rights Reserved by MedPath